Multiple Sclerosis Therapeutics Market Size Worth $39.22 Bn by 2027 – The Insight Partners

New York, Nov. 09, 2022 (GLOBE NEWSWIRE) — According to The Insight Partners new research study titled “Multiple Sclerosis Therapeutics Market Size, Share, Growth and Forecast to 2027 – COVID-19 Impact and Global Analysis – by Drug Class, Route of Administration, Distribution Channel, and Geography,” the market was valued at USD 24.02 billion in 2019 and is projected to reach USD 39.22 billion by 2027.

Download Sample PDF Brochure of Multiple Sclerosis Therapeutics Market Size – COVID-19 Impact and Global Analysis with Strategic Insights at: https://www.theinsightpartners.com/sample/TIPRE00004057/

Global Multiple Sclerosis Therapeutics Market Report Scope, Segmentations, Regional & Country Scope:

Multiple Sclerosis Therapeutics Market: Competitive Landscape and Key Developments

Merck & Co., Inc.; Novartis AG; Bayer AG; Sanofi; Bristol-Myers Squibb Company; Horizon Therapeutics plc; TEVA PHARMACEUTICAL INDUSTRIES LTD; Takeda Pharmaceutical Company Limited; F. HOFFMANN-LA ROCHE LTD.; and Biogen are among the key players operating in the global multiple sclerosis therapeutics market. These companies adopt product innovation strategies to meet the evolving customer demands worldwide and maintain their brand value in the global multiple sclerosis therapeutics market.

A few of the recent developments in the global multiple sclerosis therapeutics market are mentioned below:

In June 2020, Bristol Myers Squibb launched ZEPOSIA (ozanimod) 0.92 mg—a sphingosine-1-phosphate (S1P) receptor modulator to treat the relapsing multiple sclerosis (RMS) in adults. The 0.92-mg once-daily dose was approved by the US Food and Drug Administration (FDA) on March 25, 2020, and is also recommended for relapsing-remitting disease, clinically isolated syndrome, and active secondary progressive disease.

In August 2020, US FDA approved Novartis Kesimpta (ofatumumab). It is the first and only self-administered, targeted B-cell therapy to treat the relapsing forms of multiple sclerosis. Kesimpta’s favorable safety and powerful efficacy profile have the potential to become the first choice of treatment for the patients with MS.

In February 2021, US FDA approved Biogen’s PLEGRIDY (peginterferon beta-1a) Intramuscular (IM) Administration to treat multiple sclerosis. The new IM administration allows patients with relapsing MS, the well-characterized efficacy and safety of PLEGRIDY. PLEGRIDY has the potential for remarkably lower reactions of injection site. Due to this approval, the Biogen’s portfolio of MS treatments expanded, which also includes the subcutaneous (SC) administration of PLEGRIDY.

In August 2020, Sanofi acquired Principia Biopharma for $3.68 billion, giving the French drug manufacturer full control over the multiple sclerosis treatment the companies share. The acquisition strengthened Sanofi’s core areas of allergic diseases and autoimmune, giving the company complete control over tolebrutinib (SAR442168) and additional BTK inhibitors for further development.

Inquiry Before Purchase: https://www.theinsightpartners.com/inquiry/TIPRE00004057/

Growing Prevalence of Multiple Sclerosis (MS) Driving Multiple Sclerosis Therapeutics Market

Multiple sclerosis is a chronic disease impacting the brain, spinal cord, and optic nerves. Its symptoms include weakness, anxiety, abnormality of taste, reduced sensation, and blurred vision or vision loss. Some other signs consist of constipation, muscle stiffness, depression, thinking problems, and urinary problems.

Studies suggest that there are increasing instances of multiple sclerosis worldwide. As per the National Multiple Sclerosis Society’s study, about 1 million (up to 913,925) adults were living with multiple sclerosis in the US in 2017. An estimated prevalence of the disease was 309 cases per 100,000 people in 2010, accounting for a total of 727,344 multiple sclerosis cases among adults. As per the Government of Canada (2014–2015 estimates), over 77,000 Canadians were living with multiple sclerosis of which 3/4th were women.

The Multiple Sclerosis Society stated that about 110,000 people were suffering from the condition in the UK in 2018. It also mentioned that MS is more than twice prevalent in females. From 5,000 patients in 2017 to 6,700 in 2018, it is evident that the number of new patients diagnosed every year is also increasing.

Speak to Research Expert: https://www.theinsightpartners.com/speak-to-analyst/TIPRE00004057

Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system. The immune system attacks the nerves which causes communication problems between the brain and rest of the body. Immunosuppressant and immunomodulators, along with physiotherapy, are widely used to treat MS. 

Impact of COVID-19 on Global Multiple Sclerosis Therapeutics Market: 

COVID-19 pandemic has become the most significant challenge across the world. This challenge will be frightening especially in developing countries across the globe as it will lead to reducing imports due to disruptions in global trade. Till date no definitive treatment against COVID-19 has been established. Patients with severe health conditions, such as neurological diseases and others; are witnessing delays in such chronic disease treatment. Supply chain disruptions associated with this pandemic situation will ultimately affect the sales of products for short period. However, the supply of MS drugs has been continuous in the pandemic as pharmacies are allowed to open during the lock down. Several companies are cutting their clinical trial activities and delaying product launches in response to the COVID-19 pandemic. For instance, Bristol-Myers Squibb delayed the launch of its multiple-sclerosis drug Zeposia (ozanimod) due to the outbreak of COVID-19 pandemic.

Global Multiple Sclerosis Therapeutics Market Segmentation:

Based on drug class, the market is segmented into immunosuppressant and immunomodulators. In 2019, the immunomodulators segment accounted for larger share of the market. Growth of this segment is attributed to launch of new generic drugs and increase in adoption of immunomodulators in MS treatment. The immunosuppressant segment is likely to register higher CAGR during the forecast period. 

Directly Purchase “Single User License” of Multiple Sclerosis Therapeutics Market Growth Report (2020-2027) at: https://www.theinsightpartners.com/buy/TIPRE00004057/

The World Health Organization, Food and Drug Administration, Centers for Disease Control and Prevention, European Medicines Agency, National Center for Biotechnology Information, and National Health Service are some of the major primary and secondary sources referred for preparing this report.   

Browse Related Reports:

Allergy Diagnostics And Treatment Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Diagnostic Tests (Skin prick test, Intradermal, Patch test, In vitro); Drug class (Antihistamines, Decongestants, Corticosteroids, Mast cell Stabilizers, Leukotriene Inhibitors, Nasal Anticholinergics Immunomodulators, AutoinjecTable Epinephrine, Immunotherapy); Product Type (Instruments, Consumables, Services); Allergen Type (Food, Inhaled, Drug, Other); End User (Diagnostic Laboratories, Hospitals, Academic Research Institutes) and Geography

Oncology Biosimilars Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Product (Monoclonal Antibodies, Immunomodulators, Others); Cancer Type (Lung Cancer, Colorectal Cancer, Cervical Cancer, Breast Cancer, Stomach Cancer, Brain Cancer, Others)

Inflammatory Bowel Disease Treatment Market Forecast to 2028 –  Covid-19 Impact and Global Analysis – by Drug Class (Aminosalicyclates, Immunomodulators, TNF Inhibitors, Corticosteroids); Disease Indication (Crohn’s Disease, Ulcerative Colitis); Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)

Immunomodulators Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Product (Immunosuppressant, Immunostimulants); Application (Oncology, Respiratory, HIV, Others) and Geography

Crohn’s Disease Therapeutics Market Forecast to 2028 –  Covid-19 Impact and Global Analysis – By Drug Class (Anti-inflammatory Biologics, Non-Steroidal Anti-inflammatory drugs (NSAIDs), Corticosteroids, TNF Inhibitors, Aminosalicyclates, Immunomodulators); Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) and Geography

Atopic Dermatitis Drugs Market Forecast to 2028 –  Covid-19 Impact and Global Analysis – by Route of Administration (Topical, Injectable, Oral); Drug Class (Topical antibiotics, Topical antihistamines, Topical corticosteroids, Topical Moisturizers/Emollients, Topical calcineurin inhibitors, Immunomodulators, Off-Label Therapies, Systemic Agents, PDE4 inhibitor, Interleukin inhibitor, Interleukin inhibitor) and Geography

Ulcerative Colitis Market Forecast to 2028 –  Covid-19 Impact and Global Analysis – by Drug Type (Aminosalicylates, Corticosteroids, Immunomodulators, Antibiotics, Other Drug Types); Disease Type (Mild Ulcerative Colitis, Moderate Ulcerative Colitis, Severe Ulcerative Colitis); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Sales)

Inflammatory Bowel Disease Relief Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Drug Class (Aminosalicyclates, Immunomodulators, TNF Inhibitors, Corticosteroids); Indication (Crohn’s Disease, Ulcerative Colitis); Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)

Influenza Antiviral Drugs Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Type (Influenza A, Influenza B, Influenza C); Treatment Type (Medication, Chemoprophylaxis, Others); Mechanism of Action (Cap- dependent endonuclease inhibitor, Nuraminidase Inhibitor, Matrix-2 Protein Inhibitor, Viral Uncoatings Inhibitors, Immunomodulators); Vaccine Type (Quadrivalent, Trivalent ,Others); Routes of Administration (Oral, Parenteral, Others); End Users (Hospitals, Clinics, Specialty Clinics, Others) and Geography

Multiple Sclerosis Drugs Market Forecast to 2028 – Covid-19 Impact and Global Analysis By Drug Class (Immunomodulators, Immunosuppresants, Interferons, Others); Route Of Administration (Oral, Parenteral); Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) and Geography

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:
If you have any queries about this report or if you would like further information, please contact us:

Contact Person: Sameer Joshi
E-mail: [email protected]
Phone: +1-646-491-9876
Press Release: https://www.theinsightpartners.com/pr/multiple-sclerosis-therapeutics-market/